In its key recommendations, the President's Council onCompetitiveness report:

-- Advises the Bush Administration to oppose any legislationaimed at changing the oversight of biotechnology, and suggeststhat the Administration develop regulations instead.

-- Opposes legislative changes to the Orphan Drug Act anddirects the Food and Drug Administration to ensure that drugsgiven orphan drug designation are for truly rare diseases.

-- Supports legislation to improve the protection ofbiotechnology process patents (such as the amended form of abill introduced during the last Congress by Rep. Rick Boucher,D-Va.).

-- Calls for a White House biotechnology working group todevelop a single set of regulations to fill the gaps in the 1986Coordinated Framework for the Regulation of Biotechnology.

-- Directs the Department of Health and Human Services toissue guidelines requiring federally funded biomedicalresearchers to fully disclose financial ties with companieswhose products they are testing.

-- Calls for further study of tax issues, such as credits for smallbusinesses and companies involved in research anddevelopment, that affect biotechnology.

(c) 1997 American Health Consultants. All rights reserved.

No Comments